Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tifcemalimab by Shanghai Junshi Biosciences for Non-Small Cell Lung Cancer: Likelihood of Approval
Tifcemalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase I for Non-Small Cell Lung Cancer. According...
Toripalimab by Shanghai Junshi Biosciences for Metastatic Biliary Tract Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Metastatic Biliary Tract Cancer. According...
Tifcemalimab by Shanghai Junshi Biosciences for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Tifcemalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)....
Toripalimab by Shanghai Junshi Biosciences for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Recurrent Head And Neck Squamous...
Toripalimab by Shanghai Junshi Biosciences for Synovial Sarcoma: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Synovial Sarcoma. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction....
Toripalimab by Shanghai Junshi Biosciences for Oropharyngeal Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Oropharyngeal Cancer. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Hepatocellular Carcinoma: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase III for Hepatocellular Carcinoma. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Gastric Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Gastric Cancer. According to GlobalData,...
Tifcemalimab by Shanghai Junshi Biosciences for Small-Cell Lung Cancer: Likelihood of Approval
Tifcemalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase III for Small-Cell Lung Cancer. According to...
Toripalimab by Shanghai Junshi Biosciences for Metastatic Colorectal Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Metastatic Colorectal Cancer. According to...
Toripalimab by Shanghai Junshi Biosciences for Cervical Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Cervical Cancer. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Gallbladder Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Gallbladder Cancer. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Non-Small Cell Lung Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase III for Non-Small Cell Lung Cancer. According...
Toripalimab by Shanghai Junshi Biosciences for Rectal Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Rectal Cancer. According to GlobalData,...
Tifcemalimab by Shanghai Junshi Biosciences for Solid Tumor: Likelihood of Approval
Tifcemalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase I for Solid Tumor. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Ovarian Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Ovarian Cancer. According to GlobalData,...
JS-006 by Shanghai Junshi Biosciences for Non-Small Cell Lung Cancer: Likelihood of Approval
JS-006 is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Non-Small Cell Lung Cancer. According...
JS-006 by Shanghai Junshi Biosciences for Solid Tumor: Likelihood of Approval
JS-006 is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Solid Tumor. According to GlobalData,...
JS-006 by Shanghai Junshi Biosciences for Hepatocellular Carcinoma: Likelihood of Approval
JS-006 is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData,...